Compositions and methods for the personalized and targeted therapeutic treatment of diseases and disorders, including the treatment of pain, inflammation, and infectious diseases in a subject. In particular, labeled natural cannabinoid therapeutic compositions are provided that include a conjugate of a natural cannabinoid compound, a chelator, and a label, that when coupled with imaging may be used to determine in real time optimal dosing and targeting of particular pathways and tissues to provide personalized therapies. Combination therapies are also provided that include one or more natural cannabinoid compound and at least one active pharmaceutical ingredient.

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Disclosed is a complex for remedying or treating a retinal disease. The complex includes a hyaluronic acid or a derivative thereof, a carbon nanomaterial covalently bonded to the hyaluronic acid or the derivative thereof, and a photosensitizer bonded to the carbon nanomaterial. The complex for remedying or treating the retinal disease according to the present invention includes a hyaluronic acid-carbon nanomaterial-photosensitizer complex, thus selectively preventing the formation of active oxygen in retinal pigment epithelium cells for a relatively long period of time. Accordingly, the complex has excellent therapeutic efficacy and easily infiltrates into cells. Further, the present invention provides a composition for remedying or treating a retinal disease including the hyaluronic acid-carbon nanomaterial-photosensitizer complex.

The present invention relates to a method of preparation of formulations of lanthanide metal complexes of macrocyclic chelators which further comprise a small excess of free chelator. The method uses a solid phase-bound scavenger chelator to remove excess lanthanide metal ions, prior to the addition of a defined excess chelator. Also provided is a method of preparation of MRI contrast agents, together with solid-phase bound chelator meglumine salts useful in the methods.

Ultrastable silver nanoparticles, methods of making the same, and methods of using the same, are disclosed.

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

The application provides a method for improving the stability of a low-concentration atropine ophthalmic preparation, characterized by controlling the content of the total impurity ≤0.25% and/or a single impurity content of ≤0.05%, as well as a method for preparing the ophthalmic preparation, an atropine ophthalmic preparation prepared therefrom and use thereof in the manufacture of a medicament for preventing and/or treating vision defects.

EGCG-Zn.sup.2+ molecular complexes exhibit a significantly higher affinity than the EGCG molecule alone or Zn.sup.2+ molecule alone for binding to different SARS-CoV-2 molecular targets and show virtually complete antiviral suppressive activity (>99%) against this virus in experimental models of infection. EGCG-Zn.sup.2+ complexes have a lower toxicity than EGCG alone in transfected human cells. The combination of EGCG and Zn.sup.2+, significantly improved some key pharmacokinetic parameters of EGCG in humans. Thus, these complexes are usable as a new broad-spectrum method for chemoprophylaxis or treatment of viral diseases by using formulations containing a composition of EGCG and Zn.sup.2+ or EGCG-Zn.sup.2+ complexes in sufficient amount to reach a blood concentration with antiviral effect, minimizing human safety issues.

Disclosed herein are composite polypeptide. According to various embodiments, the composite polypeptide includes a parent polypeptide and a metal binding motif capable of forming a complex with a metal cation. The composite polypeptide may be conjugated with a linker unit having a plurality of functional elements to form a multi-functional molecular construct. Alternatively, multiple composite polypeptides may be conjugated to a linker unit to form a molecular construct, or a polypeptide bundle. Linker units suitable for conjugating with the composite polypeptide having the metal binding motif are also disclosed.

The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C.sub.15-C.sub.25) hydroxyalkanoic acid), an antioxidant, and water.